Editor's Choice: Ocular Adverse Events and Phosphodiesterase 5 Inhibitors
Joëlle E. Vergroesen, MSc; Eric F. Thee, MD; Fariba Ahmadizar, PhD; et al
Original Investigation | May 19, 2022
online first